Study guide

Heart failure assessment and treatment

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Heart failure assessment and treatment

Key Takeaways Explain This Topic AI

HFrEF therapy combines appropriate renin–angiotensin treatment, beta blockade, mineralocorticoid antagonism and SGLT2 inhibition.

Start and increase beta blockers when the patient is clinically stable.

NT-proBNP is easier to interpret than BNP during sacubitril/valsartan treatment.

Last updated: October 2026

Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure (HF) and cardiac arrhythmias represent major causes of emergency hospital admissions and cardiovascular morbidity across Australia. Effective management requires precise phenotypic classification, rapid initiation of mortality-reducing guideline-directed medical therapy (GDMT), and timely stabilization of haemodynamic decompensation and electrical instability.

Heart Failure Phenotypes and Diagnostic Evaluation

Heart failure is a complex clinical syndrome characterized by cardinal symptoms (breathlessness, orthopnoea, fatigue, ankle swelling) and clinical signs (elevated jugular venous pressure, pulmonary crackles, peripheral oedema) caused by a structural or functional cardiac abnormality that results in elevated intracardiac pressures or reduced cardiac output.

According to the universal definition and Australian guidelines, heart failure is classified into three distinct phenotypes based on left ventricular ejection fraction (LVEF):

Heart Failure with Reduced Ejection Fraction (HFrEF) : L V E F ≤ 40 % LVEF \le 40\% L V EF ≤ 40% . Characterized by impaired myocardial contractility, progressive ventricular dilatation, and eccentric remodelling. Quadruple medical therapy substantially reduces mortality and hospital admissions.

Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF) : L V E F 41 % to 49 % LVEF \text{ } 41\%\text{ to }49\% L V EF 41% to 49% . Represents a transitional phenotype that shares clinical characteristics and therapeutic responsiveness with HFrEF.

Heart Failure with Preserved Ejection Fraction (HFpEF) : L V E F ≥ 50 % LVEF \ge 50\% L V EF ≥ 50% with objective evidence of diastolic dysfunction, structural alterations (left atrial enlargement, left ventricular hypertrophy), or elevated resting/exertional left ventricular filling pressures.

Diagnostic Biomarkers & Imaging

B-type Natriuretic Peptide (BNP) & N-Terminal pro-BNP (NT-proBNP) : Released by ventricular myocytes in response to increased wall stress and volume expansion. Highly sensitive rule-out biomarkers in the acute presentation:

Acute setting: B N P < 100 pg/mL BNP < 100\text{ pg/mL} BNP < 100 pg/mL or N T - p r o B N P < 300 pg/mL NT\text{-}proBNP < 300\text{ pg/mL} NT - p ro BNP < 300 pg/mL reliably excludes acute heart failure (negative predictive value > 95 % > 95\% > 95% ).

Confounders: Levels are elevated by advanced age, renal impairment ( e G F R < 60 mL/min/1.73m 2 eGFR < 60\text{ mL/min/1.73m}^2 e GFR < 60 mL/min/1.73m 2 ), and atrial fibrillation. Conversely, levels are disproportionately lower in obese patients ( B M I ≥ 30 kg/m 2 BMI \ge 30\text{ kg/m}^2 BM I ≥ 30 kg/m 2 ).

Clinical Caveat : Sacubitril inhibits neprilysin (the enzyme that degrades BNP). Consequently, patients receiving sacubitril/valsartan have elevated circulating BNP levels; NT-proBNP must be measured instead to assess clinical response, as NT-proBNP is not a neprilysin substrate.

Transthoracic Echocardiography (TTE) : The gold standard non-invasive diagnostic investigation. Evaluates LVEF, chamber dimensions, regional wall motion abnormalities, valvular lesions, and markers of diastolic filling pressures (mitral inflow E / A E/A E / A ratio, tissue Doppler E / e ′ E/e' E / e ′ ratio, and tricuspid regurgitant jet velocity for estimating pulmonary artery systolic pressure).

Chest Radiography : Identifies signs of pulmonary venous congestion and fluid overload:

Cardiomegaly: Cardiothoracic ratio > 0.50 > 0.50 > 0.50 on a posterior-anterior view.

Vascular redistribution: Upper lobe venous diversion ("stag's antler sign").

Interstitial oedema: Peribronchial cuffing and horizontal linear densities at the lung bases ( Kerley B lines ).

Alveolar oedema: Bilateral perihilar opacities in a classic "bat-wing" or "butterfly" distribution.

Pleural effusions: Usually bilateral or right-sided greater than left-sided.

Guideline-Directed Medical Therapy (GDMT) for HFrEF

Australian guidelines (NHFA/CSANZ) endorse early, concurrent initiation and up-titration of the "Fantastic Four" foundational pillars of quadruple therapy for all patients with HFrEF ( L V E F ≤ 40 % LVEF \le 40\% L V EF ≤ 40% ) to reduce mortality and hospitalizations:

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) or ACE Inhibitor :

Sacubitril/valsartan is preferred first-line over ACE inhibitors based on the landmark PARADIGM-HF trial, which demonstrated a 20% relative reduction in cardiovascular death and heart failure hospitalization.

Critical Safety Rule : When switching a patient from an ACE inhibitor to sacubitril/valsartan, a mandatory 36-hour washout period is required between the last dose of the ACE inhibitor and the first dose of sacubitril/valsartan. Concomitant inhibition of ACE and neprilysin results in excessive bradykinin accumulation, causing catastrophic, life-threatening angioedema. A washout period is not required when switching from an Angiotensin Receptor Blocker (ARB).

If ARNI is not tolerated or subsidized, an ACE inhibitor (e.g., ramipril, perindopril) or ARB (e.g., candesartan) should be titrated to target doses.

Evidence-Based Beta-Blockers :

HFrEF beta-blockade: Use an agent supported by heart failure evidence and titrate in a stable patient. Choice depends on comorbidity, blood pressure and local guidance; avoid presenting a short list as the only agents with any evidence.

Must be initiated at low doses only when the patient is clinically stable and euvolaemic , with slow dose doubling every 2 to 4 weeks under close observation for transient fluid retention.

Mineralocorticoid Receptor Antagonists (MRAs) :

Spironolactone ( 25 to 50 mg 25\text{ to }50\text{ mg} 25 to 50 mg daily) or eplerenone ( 25 to 50 mg 25\text{ to }50\text{ mg} 25 to 50 mg daily).

Serum potassium and creatinine must be checked at baseline, 1 week, 4 weeks, and then every 3 months. Therapy must be withheld or dose halved if serum potassium exceeds 5.5 mmol/L 5.5\text{ mmol/L} 5.5 mmol/L or if renal function declines acutely.

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors :

Dapagliflozin ( 10 mg 10\text{ mg} 10 mg once daily) or empagliflozin ( 10 mg 10\text{ mg} 10 mg once daily).

SGLT2 inhibitors reduce heart-failure events across reduced, mildly reduced and preserved ejection fractions. Do not describe the composite benefit as proof of mortality reduction alone in every phenotype; also manage congestion and comorbid disease.

Device Therapies in HFrEF

Implantable Cardioverter-Defibrillator (ICD) : Indicated for primary prevention of sudden cardiac death in patients with symptomatic HFrEF ( L V E F ≤ 35 % LVEF \le 35\% L V EF ≤ 35% , NYHA Class II–III) despite at least 3 months of optimal GDMT, provided expected meaningful survival exceeds 1 year.

Cardiac Resynchronization Therapy (CRT-P / CRT-D) : Indicated for patients with L V E F ≤ 35 % LVEF \le 35\% L V EF ≤ 35% , sinus rhythm, and complete Left Bundle Branch Block (LBBB) with a QRS duration ≥ 130 to 150 ms \ge 130\text{ to }150\text{ ms} ≥ 130 to 150 ms despite optimal medical therapy, to restore ventricular mechanical synchrony.

Acute Decompensated Heart Failure & Cardiogenic Shock

Acute decompensated heart failure (ADHF) is classified using the Stevenson 2x2 hemodynamic matrix based on clinical bedside evaluation of perfusion ("warm" vs "cold") and congestion ("dry" vs "wet"):

Warm & Wet (Most Common, ~80%) : Adequate peripheral perfusion with pulmonary and systemic congestion (elevated JVP, crepitations, peripheral oedema). Managed with intravenous loop diuretics and vasodilators.

Cold & Wet (Cardiogenic Shock, ~10%) : Poor peripheral perfusion (hypotension, oliguria, cold mottled extremities, altered mental status, lactic acidosis) with systemic congestion. Requires inotropic support, vasopressors, and mechanical circulatory support.

Cold & Dry (~5%) : Hypoperfusion without congestion. Typically results from excessive diuresis; requires cautious fluid resuscitation.

Warm & Dry (~5%) : Compensated, euvolaemic state on optimal therapy.

Emergency Management of Acute Pulmonary Oedema

Positioning & Oxygenation : Sit the patient fully upright. Administer supplemental oxygen only if S p O 2 < 93 % SpO_2 < 93\% Sp O 2 ​ < 93% .

Non-invasive ventilation: In appropriate acute cardiogenic pulmonary oedema, positive airway pressure recruits alveoli, reduces respiratory work and can reduce cardiac loading. It requires close monitoring; shock, inability to protect the airway or failure to improve may require another approach.

Intravenous Loop Diuretics : Administer intravenous furosemide ( 40 to 80 mg 40\text{ to }80\text{ mg} 40 to 80 mg IV bolus, or 1 to 2 times 1\text{ to }2\text{ times} 1 to 2 times the patient's daily home oral dose). Diuretics produce rapid venodilation within minutes, followed by diuresis at 20 to 30 minutes.

Intravenous Vasodilators : If systolic blood pressure is > 110 mmHg > 110\text{ mmHg} > 110 mmHg , administer sublingual or intravenous glyceryl trinitrate (starting at 10 to 20 mcg/min 10\text{ to }20\text{ mcg/min} 10 to 20 mcg/min and titrating upward every 3 to 5 minutes). Nitrates rapidly reduce systemic venous return (preload) and left ventricular filling pressures.

Opioid Policy : Routine administration of intravenous morphine is no longer recommended in Australian acute heart failure guidelines, as registry data demonstrate an association with increased intubation rates, ICU admissions, and in-hospital mortality.

Primary references (checked 7 October 2026): Heart Foundation AF resources .